$50.87
0.27% yesterday
Nasdaq, Sep 23, 10:14 pm CET
ISIN
US5015751044
Symbol
KYMR

Kymera Therapeutics Inc Stock price

$50.87
+9.05 21.64% 1M
+17.17 50.95% 6M
+10.64 26.45% YTD
+0.89 1.78% 1Y
+29.18 134.53% 3Y
+20.89 69.68% 5Y
+17.61 52.95% 10Y
+17.61 52.95% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.14 0.27%
ISIN
US5015751044
Symbol
KYMR
Industry

Key metrics

Basic
Market capitalization
$3.6b
Enterprise Value
$3.0b
Net debt
positive
Cash
$665.5m
Shares outstanding
70.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
81.3 | 47.2
EV/Sales
66.6 | 38.6
EV/FCF
negative
P/B
3.7
Financial Health
Equity Ratio
85.4%
Return on Equity
-26.8%
ROCE
-29.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$44.7m | $77.1m
EBITDA
$-303.8m | $-283.3m
EBIT
$-311.9m | $-312.8m
Net Income
$-275.4m | $-245.8m
Free Cash Flow
$-252.9m
Growth (TTM | estimate)
Revenue
-49.5% | 63.8%
EBITDA
-73.1% | -13.6%
EBIT
-72.6% | -21.8%
Net Income
-74.5% | -9.8%
Free Cash Flow
-83.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-679.4% | -367.6%
EBIT
-697.5%
Net
-616.0% | -318.9%
Free Cash Flow
-565.7%
More
EPS
$-3.4
FCF per Share
$-3.6
Short interest
14.1%
Employees
218
Rev per Employee
$220.0k
Show more

Is Kymera Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Kymera Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Kymera Therapeutics Inc forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Kymera Therapeutics Inc forecast:

Buy
96%
Hold
4%

Financial data from Kymera Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
45 45
50% 50%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 66 66
9% 9%
147%
- Research and Development Expense 291 291
39% 39%
651%
-304 -304
73% 73%
-679%
- Depreciation and Amortization 8.11 8.11
57% 57%
18%
EBIT (Operating Income) EBIT -312 -312
73% 73%
-698%
Net Profit -275 -275
74% 74%
-616%

In millions USD.

Don't miss a Thing! We will send you all news about Kymera Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kymera Therapeutics Inc Stock News

Neutral
Seeking Alpha
14 days ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Good afternoon, everyone.
Neutral
Seeking Alpha
21 days ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jared Gollob - Chief Medical Officer Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Here we go. So welcome to the seco...
Neutral
GlobeNewsWire
21 days ago
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two ...
More Kymera Therapeutics Inc News

Company Profile

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Head office United States
CEO Nello Mainolfi
Employees 218
Founded 2015
Website www.kymeratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today